Gemma Bloemen
Principal @ Creandum
London, United Kingdom
Gemma Bloemen is a Principal at Creandum. He Attended Yale University during 2006-2010.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Gemma Bloemen invests in
Stages Gemma Bloemen invests in
Countries Gemma Bloemen invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $7M–$17M
- Series A
- $10M–$15M
Investment Focus
Industry
- Software 3 (50%)
- Artificial Intelligence 3 (50%)
- Medical 2 (33%)
- Apps 1 (17%)
- Sports 1 (17%)
Stage
- Seed 3 (50%)
- Series A 2 (33%)
- Pre-Seed 1 (17%)
Country
- United Kingdom 3 (50%)
- Sweden 1 (17%)
- Germany 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| eComID empowers global online retailers to reduce online product returns, shrink the environmental footprint, and guide shoppers to discover and buy products they'll truly love. | $17M / Seed / Aug 25, 2026 | ||
| On a mission to empower independent businesses across the UK to offer the best deliveries on Earth | $10.2M / Series A / Mar 12, 2024 | ||
| Unitary removes the complexity from AI adoption. Its Virtual Agents integrate seamlessly into existing tools and workflows, requiring no system overhauls or process redesigns. This enables organizations to adopt AI rapidly without engineering effort or upfront costs. Unitary’s model combines AI with human oversight to deliver an entire operationalworkload at human-level accuracy, backed by contractual guarantees. Customers see significant cost savings from day one, with a model that becomes even more efficient as it scales. It’s a faster, smarter path to AI-powered operations, without the usual complexity, risk, or overhead. | $15M / Series A / Oct 02, 2023 | ||
| Scarlet certifies software medical devices. We’re Europe's only Notified Body specialised in software and AI, and have crafted a certification process that is built for software, and is thus significantly more efficient.This is how we deliver on our mission to hasten the world’s transition to accessible healthcare: by enabling manufacturersto release their medical software and AI to those who need it without unnecessary delays.We are designated as a UK Approved Body by the MHRA, and an EU Notified Body by the Dutch Ministry of Health and the European Commission. | $7M / Seed / Aug 30, 2022 | ||
| On a mission to empower independent businesses across the UK to offer the best deliveries on Earth | $10.5M / Seed / Apr 06, 2022 | ||
| Exakt Health is the physio app for sports injuries. The Exakt Health app guides users through self-diagnosis for frequent sports injuries and then creates an individualized rehabilitation plan. | $586.4K / Pre-Seed / Mar 31, 2021 |
Co-Investors
About Creandum
Creandum is a European early-stage venture capital firm that focuses on investing in innovative technology companies. The firm supports founders by providing not only capital but also operational expertise and a robust network built over years in the industry.
Creandum Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Daniel Blomquist
Fund Partner
|
|||
Maria Frances
Venture Partner
|
|||
Fredrik Cassel
General Partner
|
|||
|
Gemma Bloemen
Principal
|
|||
Johan Brenner
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Gemma Bloemen invest in?
Gemma Bloemen invests primarily in Software, Artificial Intelligence and Medical startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Gemma Bloemen invest in?
Gemma Bloemen typically joins rounds of $7M–$17M at Seed and $10M–$15M at Series A. These are whole funding-round sizes, not Gemma Bloemen's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Gemma Bloemen took part in.
How do I contact Gemma Bloemen?
Public channels for Gemma Bloemen include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gemma Bloemen last invest?
The most recent investment recorded for Gemma Bloemen closed in Aug 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
